(CercleFinance.com) – Experts from the European Medicines Agency (EMA) spoke out on Friday in favor of marketing authorization for Ebglyss (lebrikizumab) from Almirall.
The EMA Committee for Medicinal Products for Human Use (CHMP) recommended approval of the drug developed by the Spanish laboratory for the treatment of mild to moderate atopic dermatitis in adults and adolescents.
According to analysts, this favorable opinion paves the way for approval of the drug by the European Commission over the next two months, before the official launch of the product, which should take place some time later.
After Ilumetri, an already marketed psoriasis treatment, this is the second leading product developed by Almirall in the field of dermatology.
RBC teams anticipate sales of 327 million euros for the drug by 2030.
Around 4:30 p.m., Almirall shares gained more than 2% on the Madrid Stock Exchange.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
